Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript November 8, 2023
Revance Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.63 EPS, expectations were $-1.1.
Operator: Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question and answer session. [Operator Instructions]....
